Ocumetics Technology Announces Closing of First Tranche of Brokered LIFE Offering Led by Centurion One Capital

(TheNewswire)

Calgary, AB – TheNewswire - January 2, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the“Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QB0) is pleased to announce that it hasclosed the first tranche of its previouslyannounced best efforts brokered privateplacement of units of the Company (the “Units”) foraggregate gross proceeds of approximately $788,380 (the “BrokeredOffering”). The Companyis also pleased to announce the closing of a concurrent non-brokeredprivate placement of Units for additional gross proceeds ofapproximately $235,450 (the “Non-Brokered Offering” and together with the Brokered Offering, the“Offerings”).

The Offerings were led by Centurion One Capital Corp.as lead agent and sole bookrunner (the “Lead Agent”) inrespect of the Brokered Offering and fiscal advisor in respect of theNon-Brokered Offering. Tingle Merrett LLP acted as counsel to theCompany, and Cassels Brock & Blackwell LLP acted as counsel to theLead Agent in connection with the Offerings.

A total of 1,706,383 Units weresold under the Offerings at a price of $0.60 per Unit (the“Issue Price”) for aggregate gross proceeds of approximately$1,023,830. Each Unit consists of one commonshare in the capital of the Company (a “Common Share”) andone Common Share purchase warrant (a “Warrant”).  EachWarrant entitles the holder to purchase one additional Common Share (a“Warrant Share”) at a price of $0.75 until December30, 2028.

The gross proceeds of the Offering are expected to beused to fund the Corporation’s first-in-human clinical trials, forongoing research and development and for general corporate purposes. Although the Corporation intends to use the proceeds of the offeringas described above, the actual allocation of proceeds may vary fromthe uses set out above, depending upon future operations, events oropportunities.

In connection with theOfferings, the Company paid an aggregate of $143,336.17 in commissions, fees and advisory fees, $61,429.79 of which werepaid through the issuance of an aggregate of 102,382 Units, and issuedan aggregate of 136,510 Common Share purchase warrants with eachwarrant entitling the holder thereof to acquire one Unit at the IssuePrice until December 30, 2028.  The Lead Agent intends to close therest of the Offerings in one or more subsequent tranches.

The Units offered for sale under the Offerings wereoffered by way of private placement (i) pursuant to the listed issuerfinancing exemption (the “Listed Issuer Financing Exemption”) undersection 5A.2 of National Instrument 45-106 – Prospectus Exemptions, as amended and supplemented by Coordinated Blanket Order45-935 – Exemptions fromCertain Conditions of the Listed Issuer FinancingExemption, and (ii) and inthe United States pursuant to available exemptions from theregistration requirements of the United States Securities Act of 1933,as amended (the “U.S.Securities Act”). Thesecurities issued under the Listed Issuer Financing Exemption will notbe subject to a statutory hold period pursuant to applicable Canadiansecurities laws.

Dean Burns (Chief Executive Officer and President),Roger Jewett (Chief Financial Officer), Garth Webb (Chief ScientificOfficer), Doyle Stulting (Chief Medical Officer), J. Barton McRobertsand Michael Edwards, all of whom are directors of the Corporation,participated in the Private Placement.  The Private Placement istherefore a “Related Party Transaction” under MultilateralInstrument 61-101 – Protection of Minority Security Holders inSpecial Transactions (“MI61-101”). The Corporation relied upon theexemptions from the minority shareholder approval and valuationrequirements set out in Sections 5.7(1)(a) and 5.5(a), respectively,of MI 61-101. The Private Placement was approved unanimously by thedirectors of the Corporation by resolution.  A material change reportregarding the Private Placement was not filed 21 days before thecompletion of the Private Placement as 21 days prior to the completionof the Private Placement, completion of thePrivate Placement was uncertain and therefore did not at that timeconstitute a material change.

This news release does not constitute an offer to sellor a solicitation of an offer to buy any of the securities in theUnited States. The securities have not been and will not be registeredunder the U.S. Securities Act or any state securities laws and may notbe offered or sold within the United States or to U.S. persons unlessregistered under the U.S. Securities Act and applicable statesecurities laws or an exemption from such registration isavailable.

ABOUT OCUMETICS

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF)(FRA: 2QB0) is a Canadian research and product development companythat is dedicated to developing advanced vision correction solutionsthat enhance the quality of life for patients. Through innovativeresearch and development, Ocumetics aims to transform the field ofophthalmology with state-of-the-art intraocular lenses and othervision-enhancing technologies.

Ocumetics is in the preclinical study stage of agame-changing technology for the ophthalmic industry. Ocumetics hasdeveloped an intraocular lens that fits within the natural lenscompartment of the eye potentially to eliminate the need forcorrective lenses. It is designed to allow the eye’s natural muscleactivity to shift focus from distance to near, providing clear visionat all distances without the help of glasses or contact lenses.

Additional information is available atwww.ocumetics.com and www.sedarplus.ca.

For further information, please contact:

Mr. Dean Burns

President and CEO

Tel: 817-874-7564

About Centurion One Capital

Centurion One Capital's mission is to ignite theworld's most visionary entrepreneurs to conquer the greatestchallenges of tomorrow, fueling their ambitions with transformativecapital, unparalleled expertise, and a global network of influentialconnections. Every interaction is guided by our core values ofrespect, integrity, commitment, excellence in execution, anduncompromising performance. We make principal investments, drawing onthe time-honored principles of merchant banking, where alignedincentives forge enduring partnerships. Centurion One Capital: Asuperior approach to investment banking.

Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this release.

CAUTIONARY NOTE REGARDINGFORWARD-LOOKING STATEMENTS:

This news release contains certain “forward-lookinginformation” within the meaning of applicable Canadian securitieslegislation. Generally, forward-lookinginformation can be identified by the use of forward-lookingterminology such as “plans”, “expects” or “does notexpect”, “is expected”, “budget”, “scheduled”,“estimates”, “forecasts”, “intends”, “anticipates” or“does not anticipate”, or “believes”, or variations of suchwords and phrases or state that certain actions, events or results“may”, “could”, “would”, “might” or “will betaken”, “occur” or “be achieved”. Forward-looking statements include, but are not limited to,statements with respect to the completion of theOffering and the anticipated Closing Datethereof; the expected receipt of regulatory and Exchange approvalsrelating to the Offering; the expected proceedsof the Offering and the anticipated use thereof; and any otheractivities, events or developments that the companies expect oranticipate will or may occur in the future.

Forward-looking statements are necessarily based upon anumber of estimates and assumptions that, while considered reasonable,are subject to known and unknown risks, uncertainties, and otherfactors which may cause the actual results and future events to differmaterially from those expressed or implied by such forward-lookingstatements. Such factors include but are not limited to: operationalmatters, historical trends, current conditions and expected futuredevelopments, access to financing as well as other considerations thatare believed to be appropriate in the circumstances. There can be noassurance that such statements will prove to be accurate, as actualresults and future events could differ materially from thoseanticipated in such statements. Accordingly, readers should not placeundue reliance on forward-looking statements. The Corporationdisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise, except as required by law.

NOT FORDISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATIONIN THE UNITED STATES

Copyright (c) 2026 TheNewswire - All rights reserved.